Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of genetic testing and analysis expert Illumina (Nasdaq: ILMN) evolved to a higher state today, jumping as much as 13.4% on more than double their average trading volume.

So what: The third-quarter results posted this morning missed revised, lower earnings estimates by a penny but made up for it with a strong view of next-quarter sales. That said, management warned that revenues depend heavily on government sales, and you just never know what Uncle Sam's research budgets will look like next year.

Now what: Illumina's success did not inspire a rally among the company's chief rivals: Affymetrics (Nasdaq: AFFX) is trading down nearly 2% in line with the overall market, Luminex (Nasdaq: LMNX) moved sideways today, and Life Technologies (Nasdaq: LIFE) bucked the trend with a very modest gain. That might be because Illumina also announced a restructuring effort to keep costs in check -- something that hurts in the short term but helps over the long haul.

Interested in more info about Illumina? Click here to add it to My Watchlist.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.